Skip to main content
    S

    Supernus Pharmaceuticals Inc (SUPN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $39.57
    -0.61 (-1.52%)

    Market Cap: $2.34B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +35.82%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.61
    Range$0.61 - $0.62
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.70-12.8%
    60d ago$0.67-7.8%
    30d ago$0.67-7.8%
    7d ago$0.66-7.3%
    Current$0.61
    Revenue Consensus
    $221M
    Range$219M - $224M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.17
    Range$1.08 - $1.25
    2 analysts
    Revenue Consensus
    $267M
    Range$260M - $271M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.17---
    Sep 26EST
    		-$0.61---
    Jun 26
    Reported Aug 3
    		$0.39$0.30+30.00%Beat-57.1%
    Mar 26
    Reported May 5
    		$0.21$0.28-25.00%Miss-52.3%
    Dec 25
    Reported Feb 24
    		$0.88$0.41+115.15%Beat+60.9%
    Sep 25
    Reported Nov 4
    		$0.61$0.82-25.61%Miss-44.5%
    Jun 25
    Reported Aug 5
    		$0.91$0.47+93.62%Beat+35.8%
    Mar 25
    Reported May 6
    		$0.44$0.37+18.92%Beat+83.3%
    Dec 24
    Reported Feb 25
    		$0.55$0.52+5.44%Beat-38.4%
    Sep 24
    Reported Nov 4
    		$1.10$0.44+150.00%Beat+358.3%
    Jun 24
    Reported Aug 6
    		$0.67$0.39+71.79%Beat+36.7%
    Mar 24
    Reported May 8
    		$0.24$0.38-36.84%Miss-64.7%
    Dec 23
    Reported Feb 27
    		$0.89$0.55+61.82%Beat+107.0%
    Sep 23
    Reported Nov 8
    		$0.24$0.08+200.00%Beat-53.8%
    Jun 23
    Reported Aug 8
    		$0.49$0.21+133.33%Beat+250.0%
    Mar 23
    Reported May 9
    		$0.68$0.31+119.35%Beat+58.1%
    Dec 22
    Reported Feb 28
    		$0.43$0.68-36.76%Miss+975.0%
    Sep 22
    Reported Nov 8
    		$0.52$0.46+13.04%Beat+30.0%
    Jun 22
    Reported Aug 4
    		$0.14N/A-51.72%Miss-67.4%
    Mar 22
    Reported May 9
    		$0.43$0.45-4.44%Miss+290.9%
    Dec 21
    Reported Feb 28
    		$0.04N/A-83.33%Miss-93.0%
    Sep 21
    Reported Nov 3
    		$0.40$0.23+73.91%Beat-45.9%
    Jun 21
    Reported Aug 4
    		$0.43$0.20+115.00%Beat-33.8%
    Mar 21
    Reported May 5
    		$0.11N/A-54.17%Miss-72.5%
    Dec 20
    Reported Feb 25
    		$0.57$0.52+9.62%Beat-8.1%
    Sep 20
    Reported Nov 3
    		$0.74$0.27+174.07%Beat+37.0%
    Jun 20
    Reported Aug 18
    		$0.65$0.42+54.76%Beat+6.6%
    Mar 20
    Reported May 5
    		$0.40$0.28+42.86%Beat+17.6%
    Dec 19
    Reported Feb 25
    		$0.62$0.59+5.08%Beat+29.2%
    Sep 19
    Reported Nov 5
    		$0.54$0.59-8.47%Miss+3.8%
    Jun 19
    Reported Aug 6
    		$0.61$0.60+1.67%Beat+7.0%
    Mar 19
    Reported May 7
    		$0.34$0.47-27.66%Miss-30.6%
    Dec 18
    Reported Feb 26
    		$0.48$0.29+65.52%Beat+9.1%
    Sep 18
    Reported Nov 6
    		$0.52$0.42+23.81%Beat+73.3%
    Jun 18
    Reported Aug 7
    		$0.57$0.45+26.67%Beat+72.7%
    Mar 18
    Reported May 8
    		$0.49$0.32+53.13%Beat+157.9%
    Dec 17
    Reported Feb 27
    		$0.44$0.27+62.96%Beat+18.9%
    Sep 17
    Reported Nov 6
    		$0.30$0.28+7.14%Beat-
    Jun 17
    Reported Aug 2
    		$0.33$0.24+37.50%Beat-
    Mar 17
    Reported May 9
    		$0.19$0.25-24.00%Miss-
    Dec 16
    Reported Jan 20
    		$0.37$0.34+8.82%Beat-

    Key Metrics

    Valuation
    P/E Ratio18.91EV/EBITDAN/A
    Price/FCF122.31xFCF Yield0.82%
    Profitability
    Profit Margin-13.20%Operating Margin-2.49%
    ROE-10.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage2.15x
    Current Ratio2.08xQuick Ratio1.84x
    Trading Statistics
    Beta0.55Avg Volume747.59K
    52-Week High$59.6852-Week Low$39.97

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$42.04
    SMA 20$42.60
    SMA 50$44.01
    SMA 200$47.82
    EMA 10$41.71
    EMA 20$42.33
    EMA 50$43.59
    EMA 200$45.66

    MACD

    Line: -0.74Signal: -0.51Hist: -0.23

    ADX

    ADX: 22.7+DI: 8.7-DI: 26.6

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down100.0
    PSAR$43.49

    Bollinger Bands

    Upper Band$44.90
    Lower Band$40.31
    %B Position1078%(Upper)
    Band Width-0.16

    RSI (14-Day)

    Neutral
    32.3

    Momentum Oscillators

    Stoch %K10.4
    Stoch %D23.3
    Williams %R-96.2
    ROC (10d)-6.2%
    Momentum-2.61
    CCI (20d)-274.7
    MFI (14d)35.4

    Volatility Measures

    ATR (14d)$1.59(4.0%)
    StdDev (20d)1.15
    Hist Vol31.8%(Moderate)

    Volume Flow

    VWAP$40.08
    OBV14.1M
    AD Line4.5M
    CMF (20d)-0.171

    Volume Metrics

    Avg Vol (20d)755.0K
    Vol Ratio1.0x
    VWMA (20d)$42.50

    Pivot Points

    R3$45.59
    R2$44.43
    R1$42.30
    Pivot Point$41.14
    S1$39.01
    S2$37.85
    S3$35.72

    Advanced Oscillators

    TSI-16.43
    Ultimate Osc35.7
    KST-35.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$219.06M$207.71M$211.57M$192.10M$165.45M$149.82M$174.16M$175.69M$168.32M$143.64M$164.31M$153.88M
    Cost of Revenue$33.67M$23.39M$23.01M$18.96M$16.83M$15.76M$26.10M$17.58M$17.92M$16.31M$19.63M$19.60M
    Gross Profit$185.39M$184.31M$188.56M$173.14M$148.63M$134.06M$148.06M$158.11M$150.41M$127.33M$144.69M$134.28M
    Operating Expenses$243.35M$192.65M$192.50M$233.37M$136.49M$144.32M$126.66M$117.26M$127.84M$130.49M$145.68M$126.14M
    R&D$29.46M$39.44M$27.83M$29.37M$22.11M$26.93M$28.65M$29.04M$26.18M$24.93M$23.35M$22.66M
    SG&A$133.64M$125.17M$122.39M$179.68M$93.55M$89.94M$79.41M$69.75M$85.90M$86.52M$81.28M$82.70M
    Operating Income$-57,963,000$-8,332,000$-3,937,000$-60,231,000$12.14M$-10,256,000$21.41M$40.84M$22.57M$-3,153,000$-996,000$8.14M
    Interest Income$2.63M$0$0$0$4.53M$0$0$0$0$0$0$0
    Interest Expense$2.31M$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-57,648,000$-5,950,000$-1,914,000$-57,954,000$16.67M$-5,831,000$26.38M$44.94M$26.30M$243,000$990,000$9.89M
    Income Tax Expense$723,000$-3,657,000$2.19M$-12,837,000$-5,830,000$6.00M$11.05M$6.45M$6.39M$119,000$-185,000$25.86M
    Net Income$-58,371,000$-2,293,000$-4,105,000$-45,117,000$22.50M$-11,827,000$15.33M$38.50M$19.92M$124,000$1.18M$-15,976,000
    EBITDA$-32,241,000$19.99M$23.60M$-34,069,000$33.47M$13.48M$44.55M$66.01M$46.66M$22.89M$23.39M$31.81M
    EBIT$-57,648,000$-5,950,000$-1,914,000$-57,954,000$12.14M$-5,831,000$26.38M$44.94M$26.30M$243,000$990,000$9.89M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SUPN

    News

    Indivior Shareholders Approve Proposed Merger with Supernus

    Indivior's shareholders have approved an all-stock merger of equals with Supernus Pharmaceuticals, Inc., with 94% of votes cast in favor. This transaction, announced in August 2026, is expected to close on November 2...

    Indivior•10/15/26•Bullish

    Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

    Argus has lowered its target price for Supernus Pharmaceuticals, Inc. (SUPN) to $40.00. The company is a specialty pharmaceutical firm focused on developing and commercializing treatments for central nervous system...

    Yahoo! Finance Canada•10/14/26•Somewhat-Bearish

    Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD By Investing.com

    Supernus Pharmaceuticals stock dropped to a 52-week low of $40.5, just above its absolute low of $40.51, representing a 16.83% decline over the past year. Despite this...

    Investing.com South Africa•10/14/26•Somewhat-Bearish

    Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD

    Supernus Pharmaceuticals stock recently hit a 52-week low of $40.5 USD, just above its absolute low of $40.51, representing a 16.83% decline over the past year. Despite this...

    Investing.com•10/14/26•Somewhat-Bearish

    Liquidity Mapping Around (SUPN) Price Events

    This article provides a liquidity mapping analysis for Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating stable neutral readings in shorter horizons which could signal an easing of a long-term weak bias. It...

    Stock Traders Daily•10/14/26•Neutral

    SUPN Valuation and Fair Value

    P/E
    18.9x
    Forward P/E
    20.2x
    P/FCF
    122.3x
    PEG
    1.5x
    P/B
    2.2x
    See GNG's fair value

    SUPN Profitability: Margins, ROIC and FCF

    Gross margin
    88.1%
    Operating margin
    -2.5%
    Net margin
    -13.2%
    ROE
    -10.5%
    FCF margin
    2.3%
    FCF yield
    0.8%

    SUPN Competitors

    CompanyTicker
    89bio IncETNB
    Prestige Brand Holdings IncPBH
    HUTCHMED DRCHCM
    UFP Technologies IncUFPT
    MBX Biosciences, Inc. Common StockMBX
    Day One Biopharmaceuticals IncDAWN
    Maravai Lifesciences Holdings IncMRVI
    Perrigo Company PLCPRGO

    Sector: Healthcare

    SUPN Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    SUPN Bull Case vs Bear Case

    Bull case

    • SUPN beat EPS estimates in 75.0% of its last 8 reported quarters.
    • SUPN grew quarterly revenue 32.4% year over year.
    • 83.3% of SUPN's analyst ratings are Buy or Strong Buy.

    Bear case

    • SUPN has a -13.2% net profit margin.

    SUPN Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    45.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.61
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About SUPN

    Does SUPN pay dividends?

    Supernus Pharmaceuticals Inc (SUPN) does not currently pay a regular dividend.

    What is SUPN's P/E ratio?

    Supernus Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 18.91.

    What is SUPN's market cap?

    Supernus Pharmaceuticals Inc (SUPN) has a market capitalization of $2.34B with a current stock price of $39.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In